Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BIOZONE (BZNE) - Dr. Frost's next OPKO
http://seekingalpha.com/article/1715672-opko-and-its-billionaire-ceo-invested-in-biozone
Planning on holding the OPK stock anyway for a long time. Long live PBTH.
Took me 15 minutes and I confirmed when returned it takes 2 weeks then opko in acct.
And I just got most of our forms today, each six pages long, plus an instruction booklet. I say forms because I had PBTH in five accounts. I guess it'll get easier after the first one. Have fun with yours too.
ScoT mailed to me yesterday. I called and she had them.
DS, According to my broker (Fidelity) the forms were to be sent out last week. Have seen nothing yet. May have to repeat call.
PBTH holders, to get the forms for the Israeli govt., contact your broker or the Transfer Agent in order to show you are citizen of Israel or not of Israel. Then return the form to your broker or TA. This is all you need and what we are waiting on for the share transfer to OPKO Health.
Investor,
Yes, The growing web of companies in which Dr. Frost has invested are very impressive - and all are speculative.
Steve
The benefits of the acquisition may take time to translate into revenue and profits, but the spurt in price of OPKO over the last few months has made it a better deal for PROLOR shareholders. A recent article on SA has recommended to buy OPKO due to its innovation pipeline, backing of Dr. Phillip Frost, and a huge short interest which may lead to a surge in demand for the stock. The acquisition is expected to broaden OPKO's portfolio, and strengthen the pipeline of therapeutic and unique diagnostic products. PROLOR's technology platforms and R&D infrastructure are expected support OPKO's growth strategy. However, it is important to remember that the stock is now trading at high valuations, mostly based on future expectations. It is true that the revenues have grown exponentially over the years, but the bottom-line has remained negative. The debt is also a bit high. On the positive side, OPKO's 4KScore diagnostic test could generate significant annual revenues (estimated at $1.8 billion) in due course, which could easily take care of the negatives in the balance sheet. Dr. Frost's active presence on the board and as an investor is a major reason to remain confident about the company's prospects. Frost looks for synergies between his various companies. For example, OPKO has an agreement with Biozone (BZNE), another company where he has a stake, to use / explore the possibilities related to Biozone's proprietary drug delivery technology (QuSomes). The delivery technology can help in reducing cost of manufacture of formulations. QuSomes are likely to be in great demand from pharmaceuticals companies who are looking for more cost effective methods of manufacture of formulations / injectables. So OPKO has a lot of potential, but the huge run up in price is surely a reason to remain a bit cautious.
And OPK hit a high of over $9.40. Somehow, I suspect that almost all PBTH holders are now happy to have been acquired by OPK.
BTW, I do not expect this trajectory to continue without pullback and consolidation. All just IMHO.
OPK - SURGED $9.23!
Good luck to all new longs in OPK. We'll see how soon this page is shut down.
Yep today appears to be the day..
Looks like today must be the day for combining PBTH into OPK. Market Value of all my PBTH disappeared this morning from my account.
Looks like about an additional 4% gain on the transfer.
John k9uwa
own a bit of both as well
The article on Dr. Frost is somewhat lacking in substance but thank you for pointing it out. It is interesting to see where he is heading and I had not yet noticed it.
Dr. Frost's investments include OPK and PBTH and those others we mentioned before. Also Ladenburg Thalmann (LTS) which I believe is the company to which you referred. I think he owns a major portion of that as well He is listed as at least a 10% owner on the link below). NIMU and SFES were too thinly traded for me to get in when I looked. Some of the entities like LTS and PGLC clearly don't fit in the health sciences mold and must have just presented good investment opportunities for his portfolio.
Interestingly, he has made no purchases at all since 7/25 in OPK. Given the strength in that stock, underpinning PBTH, it appears to have transitioned from mostly being driven by his purchases to recently building organically.
In case you don't have the tool, I use:
http://openinsider.com/insider/Frost-Phillip-Md-Et-Al/898860
Hi Steve
Yes it appears that OPK, PBTH are continuing to move upward. An interesting article in Seeking Alpha this morning on Dr. Phillip Frost.
Dr Frost article
I see that this morning both SFES +8% and NIMU +40% are both up considerably. They are both thinly traded so it doesn't take a lot of shares to make either of them move. Corporate address for both of those is the same as OPK. The article mentions some financial services company that Doc bought into and is on their BOD. LTS not sure why his interest in this one.
And gradually PBTH is catching up with OPK.
John k9uwa
Hi John,
Yeah, I guess we are not the only "Frost groupies." I have PBTH, OPK, PGLC, ROX and CDXC among his investments. Somehow I never did SafeStitch or MusclePharm. Lets hope these are all winners, with a focus on PBTH and OPK for now.
Steve
Yes voted my paltry number of shares of PBTH a couple days ago agree with BOD for the merger. I have been long OPK since early Nov 2012. Something around $4.40 range. First bought into PBTH early June 2013. I have my own self imposed limit in any one stock in both of them.
Answer to the guy who asked how his PBTH shares would be priced upon the merger? Upon the merger PBTH will cease to exist and you will be issued 0.997 shares of OPK in its place. So whatever OPK is worth at that point nearly that same price will be your replacement price in OPK.
I am also holding shares in SFES another of Dr Frost's companies. Some 31M shares of short interest in OPK and only 1M on PBTH. Dr Frost and other principals in the company 51% ownership 126M shares. Another 12% owned by mutual funds not likely they will be selling anytime soon. Shorts are about 10% with the Dr and Mutual funds at 63%. The shorts don't have much available to purchase. Dr Frosts real payoff will be when he sells the whole works to one of the big drug companies. My payoff as well.
I will really enjoy watching the short squeeze in OPK one of these days.
John k9uwa
It is virtually certain that the merger/acquisition will take place. All the legal investigations are basically "ambulance-chasing" attorneys (with apologies to one cousin who was an ambulance chaser) looking to score lead position in a class-action suit which they hope will turn up some misdeed, like the BOD not performing their fiduciary duty to shareholders. Usually, absent a smoking gun or clear self-dealing, it is hard to win such cases. Often, cases are filed simply in hopes of scoring a nuisance settlement from the company being sued, with the attorneys taking at least one-third of that. They are easy to file and these guys have the templates all ready.
If you do a google search on the names of the law firms soliciting PBTH shareholders as clients, you will see they have filed many, many similar suits on virtually every merger/acquisition.
While I personally felt that PBTH had a ladder of success ahead of it as an independent entity, I also own some OPK shares and am mollified by the higher price.
All of the foregoing is just IMHO, and does not constitute investment advice.
with OPK revenues DOUBLING last Q, PBTH shareholders see the light.
Feel a little better about the merger getting done after reading a recent article about the upcoming deal between OPK and PBTH. Frost has the power...
Frost is the biggest shareholder in both Prolor and Opko, owning 26.5% of the former and 50% of the latter. In contrast to Israeli law, under US law, Frost and his associates who are parties at interest in the deal are not banned from voting on it. This means that the vote by Opko shareholders is essentially a done deal. As for Prolor, the parties will have to secure a third of the independent shareholders to approve the merger.
yep. 95% sure this is done deal.
Got it thanks. Merger will be completed in this upcoming quarter? Hope it goes through, as I heard there is some resistence and lawyers are now involved fighting it on behalf of shareholders. Both boards agreed though, so just waiting for shareholder approval at this point. PBTH shareholders would be smart to vote yes with OPK potentially a 15-20 dollar stock in the future (with all that it has in the pipeline and of course the great Dr. Frost at the helm).
and yes. after proxy vote in a few weeks gap should close. shorts will bail.
what OPK is trading at once the day of the completed merger. .9955
Won't the gap close between PBTH and OPK as the merger date gets closer? I just added at $7.12 this morning as I like the spread, but please educate me about how the spread will actually work. I know PBTH holders will get something like .997 a share of OPK, but is it from the date you buy (so I am locked in at 7.12 or no?), or what they are both trading at on the day of the completed merger. In another words, what is the cut off date if any... or is it what they both close at on the last day of PBTH trading (as to how the PBTH shares will be consumated or converted)? TIA
Long and Strong PBTH/OPK
Agreed. Still adding when possible here
I think it is a wise move to buy as long as the spread between PBTH and OPK is large enough. It was 61 cents at the close, which puts it at about 8-9 percent. I have some of both companies shares, but am much more heavily into PBTH, basically at the limit I put into a single stock.
needs to catch up above 7s. but cheap here, so I am adding
And the arbitrage premium is getting smaller and smaller as people become more convinced the acquisition by OPK will happen.
~ $PBTH ~ Daily Par Sar Buy Signal ~ Criteria alert triggered during a recent trading session!
$PBTH has just triggered the "Parabolic SAR Buy Signals" scan criteria at Stockcharts.com
~ http://tinyurl.com/SAR-BUY ~
For a more in Depth study and DD profile, similar to the one contained in this link: ~ http://tinyurl.com/DDexample ~
Click the following link and type ticker or brief message asking me about the DD: ~ http://tinyurl.com/GET-THE-DD ~
What does the scan "Parabolic SAR Buy Signals" mean? Below is an image example and study link.
~ http://stockcharts.com/school/doku.php?id=chart_school:technical_indicators:parabolic_sar ~
To find other similar posts of "PBTH" utilize the links that follow.
Search MACDgyver's "Parabolic SAR Buy Signals" posts: ~ http://investorshub.advfn.com/boards/msgsearchbymember.aspx?searchID=251916&srchyr=2013&SearchStr=ParSarBuyScan ~
Search MACDgyver's posts for symbol "PBTH": ~ http://investorshub.advfn.com/boards/msgsearchbymember.aspx?searchID=251916&srchyr=2013&SearchStr=PBTH ~
Search Ihub for "PBTH" posts: ~ http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=PBTH ~
For more in depth training and information visit Chartschool on the Stockcharts page.
~ http://stockcharts.com/school/doku.php?id=chart_school ~
Also don't forget the Ihub Edu Channel.
~ http://investorshub.advfn.com/boards/education.aspx ~
c
I believe it's a done deal. Either way, looked cheap. GLTA
DS,
Good move. The spread between PBTH and OPK assumes the deal will not go through. PBTH has, IMHO, a great future ahead of it if it remains independent. If acquired by OPKO, this is a cheap way to buy OPK.
Steve
Day traders closing out their positions.
7:32AM PROLOR Biotech to present new data on its long-acting human growth hormone and long-acting oxyntomodulin at ENDO 2013 (PBTH) 6.15 : Data previously reported by the company confirmed that hGH-CTP appears to be safe and well tolerated and that it has the potential to be administered once-weekly to adults with growth hormone deficiency. The new data provides further information on the 'excellent' safety and tolerability profile of hGH-CTP in a variety of pre-clinical and clinical studies.
dshade, The only prices that matter ultimately are what you bought at vs where you sell. I'm well overweight in PBTH in my portfolio already and my average cost is under $5, so I'm content to sit tight. IMHO, this will be a big winner long term. Although it seems to offer lots of opportunities for traders to get in and out, that's not my temperament.
Followers
|
11
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
241
|
Created
|
12/26/02
|
Type
|
Free
|
Moderators |
http://www.prolor-biotech.com/
http://finance.yahoo.com/q/ks?s=PBTH+Key+Statistics
PROLOR Biotech, Inc., a development stage biopharmaceutical company, develops proprietary versions of already-approved therapeutic proteins. The company's technology, Carboxyl Terminal Peptide technology could be attached to an array of existing therapeutic proteins, stabilizing the therapeutic protein in the bloodstream and extending its life span without additional toxicity or loss of desired biological activity. Its products under development include Human Growth Hormone, which is used for the long-term treatment of children and adults with growth failure due to inadequate secretion of endogenous growth hormone; Erythropoietin for individuals with chronic kidney failure, chemotherapy patients, and HIV/AIDS patients on AZT, as well as for patients who may require a blood transfusion or undergo surgery where blood loss is expected; and Interferon ß that is used to reduce the frequency and severity of relapses afflicting people suffering from multiple sclerosis, as well as Factor VIIa, Factor IX; Anti-Obesity Peptide; and Glucagon-Like Peptide-1. The company was formerly known as Modigene Inc. and changed its name to PROLOR Biotech, Inc. in June 2009. PROLOR Biotech, Inc. was founded in 2001 and is based in Nes-Ziona, Israel.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |